Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Delayed NYSE			5-day change	1st Jan Change
- ^USD	-.--%		+1.73%	+0.97%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.63B 51.19B 46.83B 88.16B 6,081B 88.48B 605B 236B 3,065B 239B 234B 10,147B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.48B 65.1B 59.56B 112B 7,734B 113B 770B 301B 3,898B 304B 297B 12,905B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
27/06/24	Allergan Aesthetics Debuts Alle Payment Plans	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

Allergan plc Share Price

Stocks

AGN

IE00BY9D5467

Pharmaceuticals

Valuation : Allergan plc

Latest news : Allergan plc

Press Releases : Allergan plc

News in other languages : Allergan plc

Managers and Directors : Allergan plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	30/11/2016
Robert Michael PSD	President	55	07/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	07/05/2020
Scott Reents BRD	Director/Board Member	-	07/05/2020
Ryan Quigley BRD	Director/Board Member	-	07/05/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/05/20	James D'Arecca	Issuer sale	Controller/Auditor	19,495	0.0059%
08/05/20	Adriane Brown	Issuer sale	Director	2,916	0.0009%
08/05/20	Matthew Walsh	Issuer sale	Chief Financial Officer	67,678	0.0206%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLERGAN PLC	-.--%	+1.73%	-	-	63.66B
ELI LILLY AND COMPANY	-1.12%	-8.14%	+59.79%	+112.43%	1,060B
JOHNSON & JOHNSON	-1.57%	-2.79%	+50.59%	+59.86%	651B
ABBVIE INC.	-1.81%	-2.94%	+23.90%	+75.98%	465B
ROCHE HOLDING AG	-1.17%	-0.93%	+40.43%	+40.43%	365B
NOVARTIS AG	-2.00%	-1.95%	+23.06%	+38.92%	300B
ASTRAZENECA PLC	-0.98%	+0.53%	+2.04%	+12.13%	258B
AMGEN INC.	-0.76%	-1.21%	+50.90%	+70.45%	238B
NOVO NORDISK A/S	-3.18%	-1.40%	-15.87%	-53.79%	210B
GILEAD SCIENCES, INC.	+0.52%	+0.85%	+29.73%	+93.68%	184B
Average	-0.66%	-0.42%	+29.40%	+50.01%	379.41B
Weighted average by Cap.	-0.44%	-2.09%	+38.56%	+65.86%

	2018	2019
Net sales	15.79B 13.55B 12.69B 11.61B 21.86B 1,508B 21.94B 150B 58.65B 760B 59.27B 57.99B 2,516B	16.09B 13.81B 12.94B 11.84B 22.28B 1,537B 22.36B 153B 59.77B 775B 60.41B 59.09B 2,564B
Net income	-5.1B -4.37B -4.1B -3.75B -7.06B -487B -7.08B -48.44B -18.93B -245B -19.13B -18.72B -812B	-5.27B -4.52B -4.24B -3.88B -7.3B -504B -7.33B -50.1B -19.58B -254B -19.79B -19.36B -840B
Net Debt	21.89B 18.79B 17.6B 16.1B 30.32B 2,091B 30.43B 208B 81.32B 1,054B 82.19B 80.4B 3,489B	17.3B 14.85B 13.91B 12.73B 23.97B 1,653B 24.05B 164B 64.29B 833B 64.97B 63.56B 2,758B